# Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum Canonical URL: https://biopharmsignal.com/news/VXRT/vaxart-to-showcase-oral-vaccine-platform-and-strategic-vision-at-bio-2026-and-ta-50053d80 Ticker: VXRT Company: Vaxart Source: Vaxart Published: 2026-06-15 12:00 EST ## Summary Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of... ## Article Body Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in two upcoming events surrounding the BIO International Convention, taking place June 22-25, 2026, at the San Diego Convention Center in San Diego, CA. 2026 Taiwan Biotech Forum Date: Sunday, June 21, 2026 Location: The Westin San Diego Gaslamp Quarter Time: 1:30pm – 5:30pm PT Sean Tucker, Ph.D., Chief Scientific Officer, will participate in a panel discussing innovative therapeutic modalities in precision medicine. 2026 BIO International Convention Date: Tuesday, June 23, 2026 Location: San Diego Convention Center, Storytelling Stage (Booth #3035) Time: 3:15pm – 3:35pm PT Steve Lo, Chief Executive Officer, and Dr. Tucker will present on the innovation, development and consumer friendly approach of the company’s oral vaccine tablet platform. The discussion will highlight how targeting mucosal immunity via an oral pill could eliminate reliance on traditional needle injections and cold-chain logistics, offering a modern solution to improve global health equity and pandemic readiness. About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: FINN Partners IR@vaxart.com ## Recent Company News - 2026-07-21 12:00 EST — [Vaxart to Participate in BTIG Biotechnology Conference 2026](https://biopharmsignal.com/news/VXRT/vaxart-to-participate-in-btig-biotechnology-conference-2026-f2702b19) — Source: Vaxart - 2026-07-17 20:05 EST — [Vaxart Announces Results of Annual Meeting of Stockholders](https://biopharmsignal.com/news/VXRT/vaxart-announces-results-of-annual-meeting-of-stockholders-25ca999f) — Source: Vaxart - 2026-07-06 20:01 EST — [Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine](https://biopharmsignal.com/news/VXRT/vaxart-reports-topline-12-month-safety-data-from-the-400-participant-sentinel-sa-ad993e0f) — Source: Vaxart - 2026-07-01 20:00 EST — [Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements](https://biopharmsignal.com/news/VXRT/vaxart-enters-cooperation-agreement-with-stockholder-group-and-announces-board-a-2ed5b0dd) — Source: Vaxart - 2026-06-26 12:00 EST — [Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY](https://biopharmsignal.com/news/VXRT/vaxart-publishes-presentation-urging-shareholders-to-vote-for-all-six-of-the-com-2bf27563) — Source: Vaxart ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)